Inadequate Regulation Contributes to Mislabeled Online Cannabidiol
                        Products

Freedman, Daniel; Patel, Anup D.

doi:10.15844/pedneurbriefs-32-3

Cited by 17 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to standards from medicinal cannabis leaders, a ±10% variance in CBD content is considered an acceptable margin for correct labeling of products 38 . The results presented here add to the growing evidence 39–42 that online CBD products have a high rate of mislabeling and that there is a need for regulations and good manufacturing practices. Under‐labeled products, for example, pose the risk of adverse effects since drug–drug interactions are probable and impact serum levels when other medications are simultaneously administered to patients 39 .…”

Section: Resultsmentioning

confidence: 63%

A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells

Madsen

Eriksen

et al. 2022

Phytochemical Analysis

View full text Add to dashboard Cite

Introduction: There are several cannabidiol (CBD) transdermal patches available on the market. However, none are FDA-approved. Furthermore, not much evidence has been published about CBD release and skin permeation from such patches, so the effectiveness and reliability remain unclear.Objectives: We aimed to develop a method to determine the in vitro release and skin permeation of CBD from transdermal patches using Franz cell diffusion in combination with quantitative 1 H-NMR (qNMR). Materials and Methods:The study was conducted on CBD patches with known CBD content and six different commercially available or market-ready CBD patches using a Franz cell with a Strat-M™ membrane and with samples taken directly from the transdermal patch for qNMR analysis.Results: The use of qNMR yielded an average recovery of 100% ± 7% when samples with known CBD content were tested. Results from the testing of six commercially available patches indicated that five out of six patches did not contain the CBD amount stated by the manufacturer according to a ± 10% variance margin, of which four patches were under-labeled and one was over-labeled. The release rate of patches was determined, and significant differences between the patches were shown. Maximum release of CBD was calculated to occur after 39 to 70 h. Conclusion:The established method was proven to be a reliable means of determining the quantity and release of CBD from transdermal patches and can be used to verify CBD content and release rate in transdermal patches.

show abstract

Section: Resultsmentioning

confidence: 63%

A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells

Madsen

Eriksen

et al. 2022

Phytochemical Analysis

View full text Add to dashboard Cite

show abstract

“…Therefore, the chronic use of CBD might cause undesirable effects in aging. To sum concerns, on-line availability and accessibility to CBD to products which do not fulfill FDA standards [ 166 ], could add healthy risks due to the chronic use of CBD. If used at juvenile ages, the neuronal development might be under the influence of CBD since the brain networks are still actively developing during adolescence [ 167 ].…”

Section: Cannabinoids Seem To Be Promising But Wait! What About the Lmentioning

confidence: 99%

The Endocannabinoid System May Modulate Sleep Disorders in Aging

Murillo-Rodrı́guez

Budde

Veras

et al. 2020

View full text Add to dashboard Cite

Aging is an inevitable process that involves changes across life in multiple neurochemical, neuroanatomical, hormonal systems, and many others. In addition, these biological modifications lead to an increase in age-related sickness such as cardiovascular diseases, osteoporosis, neurodegenerative disorders, and sleep disturbances, among others that affect activities of daily life. Demographic projections have demonstrated that aging will increase its worldwide rate in the coming years. The research on chronic diseases of the elderly is important to gain insights into this growing global burden. Novel therapeutic approaches aimed for treatment of age-related pathologies have included the endocannabinoid system as an effective tool since this biological system shows beneficial effects in preclinical models. However, and despite these advances, little has been addressed in the arena of the endocannabinoid system as an option for treating sleep disorders in aging since experimental evidence suggests that some elements of the endocannabinoid system modulate the sleep-wake cycle. This article addresses this less-studied field, focusing on the likely perspective of the implication of the endocannabinoid system in the regulation of sleep problems reported in the aged. We conclude that beneficial effects regarding the putative efficacy of the endocannabinoid system as therapeutic tools in aging is either inconclusive or still missing.

show abstract

“…For instance, a new study published in JAMA states that only 30.95% of sampled CBD-containing products were accurately labeled. 34,35 They TO CBD OR NOT TO CBD?…”

Section: Risks Of Cbdmentioning

confidence: 99%